Navigation Links
Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
Date:10/4/2007

Data Safety Monitoring Board Recommends Continuing Study

NEW YORK, Oct. 4 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals, Inc. (Amex: IMM) announced today the completion of interim analysis of its Phase III pivotal clinical trial of Immtech's oral drug candidate, pafuramidine. An independent Data Safety Monitoring Board (DSMB) conducted the interim analysis and recommended that the trial should continue as planned. The trial is evaluating the safety and tolerability of pafuramidine, and comparing pafuramidine's efficacy to pentamidine, a non-oral drug, in treating Human African Tryanosomiasis (HAT), also know as African sleeping sickness.

African sleeping sickness is a fatal, vector-borne parasitic disease spread by tsetse flies that threatens approximately 60 million people in sub- Saharan Africa. Current treatments for the first stage of the disease include pentamidine and suramin. Both of these intravenous drugs are associated with reported toxic side effects. If approved, pafuramidine could become the first safe and effective oral treatment for first-stage African sleeping sickness.

Carol Olson, MD, PhD, Immtech's Sr. Vice President and Chief Medical Officer stated, "Successfully completing pafuramidine's Phase III interim analysis is a major milestone on the path to registering pafuramidine for treatment of African sleeping sickness. The next major milestone will be to have the remaining patients complete the 12-month follow up protocol and for Immtech to prepare the documents for the NDA submission. We aim to have pafuramidine approved to combat this devastating infectious disease."

Enrollment in this trial was completed earlier in 2007, and all patients are expected to complete
'/>"/>

SOURCE Immtech Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Sygnis Pharma AG announces date for presentation of clinical results
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... 23, 2014 Pharmavite LLC announced that Timothy ... officer effective immediately. Toll recently served as Pharmavite,s executive ... category management, private label and sales administration in ... global role, Toll will expand his responsibilities to include ... "Toll,s appointment to chief customer officer is part ...
(Date:7/23/2014)... 23, 2014 Research and Markets ... "Global Electrophysiology Ablation Catheters Market 2014-2018" report ... http://photos.prnewswire.com/prnh/20130307/600769 Catheter ablation is a ... faulty electrical pathways from sections of the heart ... cardiac arrhythmias). Cardiac arrhythmias can be of several ...
(Date:7/23/2014)... , July 23, 2014 PositiveID ... Fla. , is an emerging player in ... systems for bio-threat detection and rapid medical testing. ... M-BAND (Microfluidic Bio-agent Autonomous Networked Detector), was developed ... Security ("DHS") Science & Technology directorate, and $30 ...
Breaking Medicine Technology:Global Electrophysiology Ablation Catheters Market 2014-2018: Key Vendors are Boston Scientific, Johnson & Johnson, Medtronic and St. Jude Medical 2Global Electrophysiology Ablation Catheters Market 2014-2018: Key Vendors are Boston Scientific, Johnson & Johnson, Medtronic and St. Jude Medical 3PositiveID Analyst Inspection: Emerging Contender in BioThreat Detection - First Ever Revenue Guidance and Backlog Position Company for Increased Visibility and Traction - by SmallCapTraders.com 2
... N.J., Oct. 27 Systech International, innovator of ... in labeling technology, today announced that they are ... at Pack Expo 2010 in Chicago on October ... a first-hand look at an end of packaging ...
... CRANFORD, N.J., Oct. 27 Alan L. Rubino, former ... emerging pharmaceutical companies, and Timothy G. Rothwell, former Chairman, ... form New American Therapeutics, Inc.   Mr. ... Rothwell will function as the company,s Chairman.  The company,s ...
Cached Medicine Technology:Systech and Marchesini Showcase Complete Serialization Line at Pack Expo 2010 2Systech and Marchesini Showcase Complete Serialization Line at Pack Expo 2010 3Veteran Pharmaceutical Executives Form New American Therapeutics, Inc. 2
(Date:7/23/2014)... Steven Reinberg HealthDay ... -- Many obese and overweight American children and teens ... is fine, U.S. health officials reported Wednesday. "Being ... such as high blood pressure, high cholesterol and diabetes," ... the U.S. Centers for Disease Control and Prevention,s National ...
(Date:7/23/2014)... 2014 Home Care Assistance Calgary ... seniors, is proud to announce the next installment in ... a wide range of health and wellness-related fields. The ... award-winning author Nancy Kriseman, and will cover the most ... burnout by becoming more self-aware. In particular, Nancy will ...
(Date:7/23/2014)... new study supports a growing body of research ... steroid hormones in treating postmenopausal breast cancer, with ... than with standard anti-hormone therapies. The study will ... open-access journal Reproductive Biology and Endocrinology . ... cancer in women in the United States. Approximately ...
(Date:7/23/2014)... DC (PRWEB) July 23, 2014 ... for ATA 2015, ATA’s twentieth annual meeting and ... The meeting, expected to attract over 5,000 attendees ... will take place May 3-5, 2015, in Los ... most renowned healthcare technology professionals from researchers, clinicians, ...
(Date:7/23/2014)... X syndrome ( FXS ) is a genetic disorder ... on the autistic spectrum, as well as cognitive deficits. ... impairment and the most common cause of autism. , ... have published a study that sheds light ... online today (July 23) in the Journal of ...
Breaking Medicine News(10 mins):Health News:Many Obese U.S. Kids Think They're Thinner Than They Are 2Health News:Many Obese U.S. Kids Think They're Thinner Than They Are 3Health News:Home Care Assistance Calgary to Host Public Webinar on the Topic of Caregiver Mindfulness 2Health News:Home Care Assistance Calgary to Host Public Webinar on the Topic of Caregiver Mindfulness 3Health News:Hormones after breast cancer: Not fuel for the fire after all? 2Health News:Hormones after breast cancer: Not fuel for the fire after all? 3Health News:Hormones after breast cancer: Not fuel for the fire after all? 4Health News:Hormones after breast cancer: Not fuel for the fire after all? 5Health News:ATA Seeks Speakers to Present at the World’s Largest Telemedicine, mHealth and Telehealth Conference 2Health News:Study links enzyme to autistic behaviors 2Health News:Study links enzyme to autistic behaviors 3
... provides the strongest evidence yet that a key portion of ... assessment// for toxins is wrong when it comes to measuring ... a scientist at the University of Massachusetts Amherst. The findings, ... 13 strains of yeast using 2,200 drugs, are published in ...
... suffering from chronic diseases are faced with uncertainty and ... Some may feel embarrassed to trouble others with their ... in Toronto, can expect to be linked to a ... themselves actively in their treatment. ,This online ...
... stressful conditions provide immunity// to face stressors which they ... ,Scientists from National Institute of Mental Health (NIMH) have ... against such hard knocks - the circuitry of resilience. ... hub, the prefrontal cortex, but also altered it so ...
... with calories. Most often, despite knowing that a particular dish ... because we are unaware of how many extra calories actually ... would take to burn those calories. , ,A ... diet-calorie reckoner, has enabled a true account of the amount ...
... of the lowest premium rise of about 4 per cent ... equates to about $1.50 a week extra on a typical ... The private cover will also be expanded to include a ... at home. ,Health Minister Tony Abbott is putting ...
... (SE) is present in eggs sometimes, and when preparations //made ... cause illness. The FDA (The U. S. Food and Drug ... follow food safety practices to avoid egg-related illness. ... and some types of stuffing, contain eggs that are raw ...
Cached Medicine News:Health News:New Study Challenges How Regulators Determine Risk 2Health News:An Online Portal To Aid Kidney Patients 2Health News:Prior Experience to Stress Acts as an Immunization 2
... The Self-Cath family of ... patients a variety of ... Each catheter is ... grade PVC and has ...
... The Self-Cath family of ... patients a variety of ... Each catheter is ... grade PVC and has ...
IMMCO ANA Elisa meets the guidelines for the laboratory diagnosis and monitoring of systemic autoimmune rheumatic diseases intended for the use of clinical pathologists and laboratory physicians....
... is engineered to distribute contact pressure evenly over ... back, to maximize stability and patient comfort. ... readily conformable to patient anatomy, to provide a ... wool liner is standard on both units, as ...
Medicine Products: